Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
| ▸ | USP2 | O75604 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | ACE | P12821 | 1/20 | 0.78 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.78 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.78 |
| ▸ | PDE4A | P27815 | 1/20 | 0.78 |
| ▸ | HTR2A | P28223 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13382771 | 0.94 | PPARG (0.75) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL8268211 | 0.92 | PPARG (0.80) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL9565910 | 0.91 | PPARG (0.74) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL16456732 | 0.90 | PPARG (0.70) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL12664495 | 0.90 | PPARG (0.77) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL1249733 | 0.89 | PPARG (0.76) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL9091775 | 0.89 | PPARG (0.78) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL1249891 | 0.89 | PPARG (0.76) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL4244974 | 0.89 | PPARG (0.71) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL809909 | 0.88 | PPARG (0.78) | PPARGKDM4EABCC3ABCC4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170835-A1 | PROCESS FOR PREPARING TELMISARTAN | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2010-04-07 | — | — | EP | claimed |
| WO-2009004064-A1 | PROCESS FOR PREPARING TELMISARTAN | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2009-01-08 | — | — | WO | claimed |
| EP-4719430-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF RENAL DISEASES AND/OR HYPERTENSION IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719429-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024240633-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF RENAL DISEASES AND/OR HYPERTENSION IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND TELMISARTAN | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024240632-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-11-28 | — | — | WO | disclosed |
| US-8993778-B2 | Process for manufacture of telmisartan | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-31 | — | — | US | disclosed |
| EP-2279159-B1 | 2'-HALOBIPHENYL-4-YL INTERMEDIATES IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS | LEK PHARMACEUTICALS (SI) | 2013-12-04 | — | — | EP | disclosed |
| US-20130137878-A1 | PROCESS FOR MANUFACTURE OF TELMISARTAN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| US-8410285-B2 | 2′-halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists | LEK PHARMACEUTICALS D.D. (SI) | 2013-04-02 | — | — | US | disclosed |
| EP-2443094-B1 | PROCESS FOR THE PREPARATION OF TELMISARTAN | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2013-03-20 | — | — | EP | disclosed |
| US-20100152259-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2170835-A1 | PROCESS FOR PREPARING TELMISARTAN | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009115584-A2 | 2'-HALOBIPHENYL-4-YL INTERMEDIATES IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS | LEK PHARMACEUTICALS D.D. (SI) | 2009-09-24 | — | — | WO | disclosed |
| EP-2103588-A1 | 2'-Halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists | Lek Pharmaceuticals D.D. (SI) | 2009-09-23 | — | — | EP | disclosed |
| EP-2103588-A1 | 2'-Halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists | Lek Pharmaceuticals D.D. (SI) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009004064-A1 | PROCESS FOR PREPARING TELMISARTAN | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2009-01-08 | — | — | WO | disclosed |
| EP-1144386-B1 | TELMISARTAN POLYMORPHS, METHODS FOR PRODUCING SAME AND THEIR USE IN THE PREPARATION OF A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1144386-A1 | TELMISARTAN POLYMORPHS, METHODS FOR PRODUCING SAME AND THEIR USE IN THE PREPARATION OF A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043370-A1 | TELMISARTAN POLYMORPHS, METHODS FOR PRODUCING SAME AND THEIR USE IN THE PREPARATION OF A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137878-A1 | PROCESS FOR MANUFACTURE OF TELMISARTAN | REN, ACE, AGT | PPARG 2976/4885KDM4E 196/4885ABCC3 4183/4885 |
| US-20100152259-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | PPARG 2546/4885KDM4E 1893/4885ABCC3 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.